EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses

Saori Kin, Yuji Oe iD, Shun Ishigaki, Ichiro Fujio, Mariko Miyazaki, Tetsuhiro Tanaka

The FASEB Journal · 2026

DOI: 10.1096/fj.202601271rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Saori Kin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Graduate School of Medicine, Tohoku University, Sendai, Japan. Hauptthemen laut MEDLINE: Fibrosis, Adenine, Disulfiram, Inflammation. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Eli Lilly Japan K.K. Innovation Research Grand 2024, Koyanagi Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is partly driven by excessive innate immune activation, which contributes to progressive renal injury and fibrosis. Disulfiram (DSF), an approved treatment for alcohol dependence, has recently emerged as an inhibitor of innate immune responses such as pyroptosis. In this study, we investigated whether DSF attenuates kidney injury in adenine‐induced nephropathy and explored the underlying mechanisms. DSF treatment markedly ameliorated kidney injury in adenine‐induced nephropathy, accompanied by suppression of inflammatory cell infiltration and inflammasome‐ and pyroptosis‐related markers. RNA sequencing revealed restoration of disrupted fatty acid metabolism in the kidneys following DSF treatment. Furthermore, DSF alleviated DNA damage, cellular senescence, and fibrosis. Importantly, activation of gasdermin D, a central executor of pyroptosis, was closely associated with disease severity in human CKD biopsy samples, supporting the clinical relevance of this pathway. Collectively, these findings suggest a potential role for DSF in modulating inflammatory and immunometabolic pathways in CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosisAdenineDisulfiramInflammationKidneyRenal Insufficiency, ChronicAnimalsHumansMiceInflammasomesMaleMice, Inbred C57BLPyroptosisCellular Senescence

Stichwörter der Autor:innen

cellular senescencefatty acid oxidationinflammasomepyroptosisrenal fibrosis

Substanzen

AdenineDisulfiramInflammasomes

Autor:innen und Institutionen

  • Department of Nephrology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • School of Medicine, Tohoku University, Sendai, Japan.

ORCID-Profile: Yuji Oe

Förderung

  • MEXT | Japan Society for the Promotion of Science (JSPS)
  • Eli Lilly Japan K.K. Innovation Research Grand 2024
  • Koyanagi Foundation
  • Japan Kidney Foundation
  • Miyagi Kidney Foundation
  • Kidney Foundation, Japan

Zitieren

APA

Kin, S., Oe, Y., Ishigaki, S., Fujio, I., Miyazaki, M., & Tanaka, T. (2026). Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses. The FASEB Journal. https://doi.org/10.1096/fj.202601271rr

Vancouver

Kin S, Oe Y, Ishigaki S, Fujio I, Miyazaki M, Tanaka T. Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses. The FASEB Journal. 2026. doi:10.1096/fj.202601271rr

BibTeX
@article{Kin2026,
  author = {Kin, Saori and Oe, Yuji and Ishigaki, Shun and Fujio, Ichiro and Miyazaki, Mariko and Tanaka, Tetsuhiro},
  title = {Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses},
  journal = {The FASEB Journal},
  year = {2026},
  doi = {10.1096/fj.202601271rr}
}
Kostenlos starten →